Lazard Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Lazard Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,294	Closed	-$76K	–	2465
2023 Q4	$76K	Buy	+1,294	New	+$72.7K	﹤0.01%	1767
2022 Q1	–	Sell	-348	Closed	-$51K	–	2589
2021 Q4	$51K	Sell	348 -4,287	-92%	-$666K	﹤0.01%	1736
2021 Q3	$819K	Buy	+4,635	New	+$746K	﹤0.01%	1098
2020 Q3	–	Sell	-19	Closed	-$2K	–	1772
2020 Q2	$2K	Buy	+19	New	+$1.84K	﹤0.01%	1574
2018 Q1	–	Sell	-20,383	Closed	-$371K	–	1137
2017 Q4	$371K	Buy	+20,383	New	+$316K	﹤0.01%	806

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lazard Asset Management's MRTX Position: Q1 2024 in Review

Lazard Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,294 shares — an estimated $76K sold.

Lazard Asset Management first reported a position in MRTX in Q4 2017 and held it in 5 quarters. The position peaked at $819K in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Lazard Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Lazard Asset Management sold 1,294 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $76K.
Lazard Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
Lazard Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $819K in Q3 2021.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Lazard Asset Management's 13F filing for Q1 2024, filed 14 May 2024.